Royal Bank of Canada
VOR icon

Royal Bank of Canada’s Vor Biopharma VOR Stock Holding History

Royal Bank of Canada’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Buy
199
+192
+2,743% +$2.71K ﹤0.01% 6532
2025
Q4 		$0 Buy
7
+5
+250% +$93 ﹤0.01% 7679
2025
Q3 		$0 Sell
2
-1
-33% -$40 ﹤0.01% 7563
2025
Q2 		$0 Hold
3
– – ﹤0.01% 7377
2025
Q1 		$0 Hold
3
– – ﹤0.01% 7263
2024
Q4 		$0 Hold
3
– – ﹤0.01% 7286
2024
Q3 		$0 Buy
+3
New +$55 ﹤0.01% 7502
2024
Q2 		– Sell
-44
Closed -$2K – 7580
2024
Q1 		$2K Sell
44
-670
-94% -$29.4K ﹤0.01% 6710
2023
Q4 		$32K Buy
714
+357
+100% +$14.7K ﹤0.01% 6170
2023
Q3 		$15K Buy
357
+160
+81% +$8.68K ﹤0.01% 6291
2023
Q2 		$12K Buy
+197
New +$18K ﹤0.01% 6428
2023
Q1 		– Sell
-42
Closed -$6K – 7524
2022
Q4 		$6K Sell
42
-37
-47% -$3.66K ﹤0.01% 6702
2022
Q3 		$6K Buy
+79
New +$7.77K ﹤0.01% 6676
2022
Q2 		– Sell
-58
Closed -$7K – 7748
2022
Q1 		$7K Sell
58
-133
-70% -$22.6K ﹤0.01% 7136
2021
Q4 		$44K Buy
191
+96
+101% +$27.7K ﹤0.01% 6441
2021
Q3 		$30K Buy
95
+56
+144% +$16.6K ﹤0.01% 6473
2021
Q2 		$15K Sell
39
-15
-28% -$7.4K ﹤0.01% 6711
2021
Q1 		$46K Buy
+54
New +$45.7K ﹤0.01% 5941

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's VOR Position: Q1 2026 in Review

Royal Bank of Canada increased its Vor Biopharma (VOR) stake by 2,743% in Q1 2026, buying an estimated $2.71K and bringing the position to 199 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6532.

Royal Bank of Canada first reported a position in VOR in Q1 2021 and has held it in 18 quarters since. The position peaked at $46K in Q1 2021. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Royal Bank of Canada held 199 shares of Vor Biopharma worth $4K as of Q1 2026.
  • Royal Bank of Canada bought 192 Vor Biopharma shares in Q1 2026, an estimated $2.71K.
  • Vor Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6532 holding.
  • Royal Bank of Canada first reported a position in Vor Biopharma in Q1 2021 and has held it in 18 quarters since.
  • Royal Bank of Canada's Vor Biopharma position peaked at $46K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.